Cargando…

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria

Alzheimer’s disease (AD) is the most common type of dementia and affects millions of adults over the age of 60 years. Accurate diagnosis relies on multiple modalities, including neuropsychological testing, cerebrospinal fluid (CSF) biomarkers, and amyloid positron emission tomography (PET) imaging....

Descripción completa

Detalles Bibliográficos
Autores principales:	Major, Catherine K, Okhravi, Hamid R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988618/ https://www.ncbi.nlm.nih.gov/pubmed/33777569 http://dx.doi.org/10.7759/cureus.13481

Ejemplares similares

β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns
por: Jiang, Chenyang, et al.
Publicado: (2022)

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
por: Palmqvist, Sebastian, et al.
Publicado: (2016)

Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients
por: Kim, Hyun Jae, et al.
Publicado: (2019)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
por: Maschio, Cinzia, et al.
Publicado: (2022)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Positron Emission Tomography (PET) Scan as a Diagnostic Tool for Giant Cell Arteritis
por: Ramachandran, Akshaya, et al.
Publicado: (2023)

Statistical Parametric Mapping in Amyloid Positron Emission Tomography
por: Smith, Natasha M., et al.
Publicado: (2022)

Detection of amyloid in Alzheimer’s disease with positron emission tomography using [(11)C]AZD2184
por: Nyberg, Svante, et al.
Publicado: (2009)

Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains
por: McLean, Daniel, et al.
Publicado: (2012)

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease
por: Tian, Mei, et al.
Publicado: (2022)

Discordant findings of different positron emission tomography/CT tracers in a case of glioblastoma
por: Kumar, Ram Elumalai, et al.
Publicado: (2021)

Discordant Amyloid Status Diagnosis in Alzheimer’s Disease
por: García-Vallés, Lorena, et al.
Publicado: (2022)

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2019)

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
por: Lin, Szu-Ying, et al.
Publicado: (2019)

Contribution of Positron Emission Tomography-Computed Tomography (PET/CT) to the Diagnosis of Endocarditis Due to an Infected Pacemaker Associated With Spondylodiscitis
por: Kalkinis, Antonios, et al.
Publicado: (2023)

Zipline Into a Case of Spontaneous Cerebrospinal Fluid Rhinorrhea
por: Haseeb, Shahan, et al.
Publicado: (2021)

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes
por: Weston, Philip S.J., et al.
Publicado: (2015)

Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis
por: Lancini, Elisa, et al.
Publicado: (2023)

Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
por: Sha, Sharon J, et al.
Publicado: (2015)

Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease
por: Grimmer, Timo, et al.
Publicado: (2012)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease
por: Fonteh, Alfred N., et al.
Publicado: (2015)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2020)

A Rare Case of Spontaneous Recurrent Cerebrospinal Fluid Rhinorrhea
por: Wang, Wen, et al.
Publicado: (2019)

Persistent Cerebrospinal Fluid Leukocytosis: Could this be Idiopathic Intracranial Hypertension?
por: Malik, Waseem T, et al.
Publicado: (2019)

Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography
por: Tripathi, Shailendra Mohan, et al.
Publicado: (2021)

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Amyloid deposition in semantic dementia: a positron emission tomography study
por: Brown, Eric E., et al.
Publicado: (2016)

Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice
por: Franceschi, Ana M., et al.
Publicado: (2022)

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qneuvn1tu34j44brtm4hqr3nis